In March’s largest biotech deal, the Belgian firm ThromboGenics NV (Euronext: THR) is entering into an agreement with Novartis AG (NYSE: NVS) for the commercialization of ocriplasmin outside of the United States. This product candidate is indicated for the treatment...
Brought to you by www.DealSearchOnline.com May 21, 2012 Issue: Recent Health Care M&A Deals Spotlight on: Long-Term Care Spotlight on: Venture Capital Conference Calendar Recent Health Care M&A Deals BIOTECHNOLOGY Acquirer Target Price...
Alder BioPharmaceuticals, a Washington-based biopharma focused on antibody therapeutics, recently closed on a $38.0 million Series D financing. This comes four years after the company’s Series C round. The current round was led by new investor Novo Ventures and joined...
Brought to you by www.DealSearchOnline.com May 14, 2012 Issue: Recent Health Care M&A Deals Watson Buys Actavis– Takes Over Number Three Spot In Generic Pharma Spotlight on: Hospitals Conference Calendar Recent Health Care M&A Deals...
Integris Health is entering into a joint venture with Health Management Associates (NYSE: HMA) to operate five acute care hospitals in Oklahoma with a combined total of 226 beds. Under terms of the deal, HMA is paying $60.0 million for an 80% ownership interest in...
Takes Over Number Three Spot In Generic Pharma The Great Recession is the gift that keeps on giving. The market plunge beginning in 2007, coupled with the Credit Crunch of 2008-09, raised the level of uncertainty, risk and, therefore, opportunity in the health care...